Cannabinoid pharmacology: Research on medicinal cannabins and its therapeutic application

Cannabinoids, the active compounds in Cannabis sativa, have garnered significant attention due to their diverse pharmacological effects, primarily mediated through cannabinoid receptors, CB1 and CB2. CB1 receptors, predominantly found in the central nervous system, are involved in regulating various physiological processes, including pain perception, appetite, and memory, while CB2 receptors, primarily located in immune tissues, play a role in modulating immune responses. The psychoactive component, Δ9-tetrahydrocannabinol (THC), functions as a partial agonist of both CB1 and CB2 receptors, eliciting effects on gastrointestinal, hepatic, and cardiovascular systems. In contrast, cannabidiol (CBD), a non-psychoactive cannabinoid, interacts with various receptors and channels, demonstrating potential therapeutic benefits, particularly in neuroprotection and anti-inflammatory responses. The endocannabinoid system (ECS), comprising endogenous ligands like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), along with their metabolic enzymes, plays a crucial role in maintaining physiological homeostasis. These endocannabinoids are synthesized on demand and act upon CB receptors to influence a wide range of biological functions. Synthetic cannabinoids, such as dronabinol and nabiximols, have been developed for therapeutic use, particularly in managing chemotherapy-induced nausea, pain, and spasticity in multiple sclerosis. Historically, Cannabis sativa has been used for its medicinal properties across various cultures. The recent surge in research has provided insights into the complex interactions between cannabinoids and the ECS, paving the way for novel therapeutic applications. However, the psychoactive nature of some cannabinoids and the potential for adverse effects necessitate further investigation to fully harness their medicinal potential.